A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
NCT06226883
Recruiting
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 2 active dose regimens of MORF-057 in adult study participants with moderately to severely active Crohn's disease (CD).
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
05/19/2025
Locations: Clinical Study Site, Lancaster, California +138 locations
Conditions: Inflammatory Bowel Diseases, Crohn's Disease
Register for Updates
Impact of Preoperative Opioid-free Multimodal Analgesia on Time to Trial of Void in Ambulatory Urogynecologic Surgeries
NCT06379425
Recruiting
This is a double-arm randomized control trial evaluating the impact of preoperative opioid-free analgesia on time to trial of void in ambulatory urogynecologic surgeries. The investigators hypothesize that receipt of acetaminophen, celecoxib and gabapentin preoperatively versus acetaminophen alone will reduce the time to trial of void in patients undergoing same-day minor urogynecologic procedures.
Gender:
FEMALE
Ages:
All
Trial Updated:
05/19/2025
Locations: Northwell Health South Shore Surgery Center, Bay Shore, New York
Conditions: Pain, Postoperative, Postoperative Pain, Acute
Register for Updates
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
NCT06541262
Recruiting
The purpose of this study is to evaluate the investigational drug, silmitasertib (a pill taken by mouth), in combination with FDA approved drugs for solid tumors. An investigational drug is one that has not been approved by the U.S. Food \& Drug Administration (FDA), or any other regulatory authorities around the world for use alone or in combination with any drug, for the condition or illness it is being used to treat. The goals of this part of the study are: * Establish a recommended dose of... Read More
Gender:
ALL
Ages:
30 years and below
Trial Updated:
05/19/2025
Locations: Arnold Palmer Hospital for Children, Orlando, Florida +4 locations
Conditions: Neuroblastoma Recurrent, Ewing's Sarcoma Recurrent, Osteosarcoma Recurrent, Rhabdomyosarcoma Recurrent, Liposarcoma Recurrent
Register for Updates
A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration
NCT06664502
Recruiting
EYE-TIE-201 is a 2-part study to investigate the safety and effectiveness of a new drug being developed called EYE201. All participants in the study will receive a total of 3 injections of EYE201 into the study eye, spaced at 4 weeks apart. In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of EYE201 will be assessed at increasing doses in branch retinal vein occlusion (BRVO) participants. Approximately 12 participants will be entered in this part of the s... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Scottsdale, Arizona, Scottsdale, Arizona +26 locations
Conditions: Diabetic Macular Edema (DME), Neovascular Age-related Macular Degeneration (NVAMD), BRVO - Branch Retinal Vein Occlusion
Register for Updates
Remote Fetal Monitoring in High Risk Pregnancies
NCT06822439
Recruiting
Antenatal nonstress tests (NSTs) are performed to assess fetal health and are used as a cost-effective test that can be widely administered. However, an NST is operator-dependent due to the nature of Doppler ultrasound and is primarily performed in a clinic and hospital setting. The ability to conduct a clinically valuable test at home would address access to care issues faced by numerous women in the United States and reduce the workload on healthcare clinicians facing a shortage of human reso... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: High Risk Pregnancy, Remote Patient Monitoring, Diabetes, Hypertension
Register for Updates
A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))
NCT05731128
Recruiting
The protocol of this Phase 2 clinical trial consists of a double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of dupilumab in participants with moderately to severely active Ulcerative Colitis (UC) with an eosinophilic phenotype. Screening period: 2 to up to 4 weeks Treatment period: 52-week investigational medicinal product (IMP) intervention (dupilumab or matching placebo) from Week 0 to Week 52 Open-label arm (optional): administration of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/18/2025
Locations: Om Research- Site Number : 8400029, Apple Valley, California +76 locations
Conditions: Colitis Ulcerative
Register for Updates
Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis
NCT06298019
Recruiting
The goal of this clinical trial is to characterize to understand the effects of a type of cell therapy called Chimeric Antigen Receptor T lymphocyte (CAR T) therapy in adult patients with the autoimmune disease dermatomyositis. This study will utilize a technology that modifies a type of white blood cell called the cytotoxic T lymphocyte-this T cell normally functions in the immune system to kill infected or potentially harmful cells in the body. In CAR T therapy, the patients' white blood cells... Read More
Gender:
ALL
Ages:
Between 25 years and 72 years
Trial Updated:
05/18/2025
Locations: Stanford University, Palo Alto, California +1 locations
Conditions: Dermatomyositis
Register for Updates
A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults
NCT06382311
Recruiting
The aim of this study is to evaluate the safety, reactogenicity and immunogenicity of the Flu Pandemic messenger RNA (mRNA) vaccine (including dose-finding and dose-confirmation) administered in healthy adults 18 to 85 years of age.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
05/18/2025
Locations: GSK Investigational Site, Anniston, Alabama +20 locations
Conditions: Influenza, Human
Register for Updates
Humidity in Incubators for Tiny Infants
NCT06399861
Recruiting
The objective of the study is to assess 2 different initial incubator humidification protocols for infants \<25 weeks' gestation admitted to the neonatal intensive care unit (NICU). The hypothesis is that a higher starting humidity decreases dehydration and results in no difference in survival or morbidity. Higher (90%) and lower (70%) starting humidity will be compared.
Gender:
ALL
Ages:
Between 0 days and 1 day
Trial Updated:
05/18/2025
Locations: Nationwide Children's Hospital - Grant Medical Center, Columbus, Ohio +5 locations
Conditions: Extremely Premature Infant
Register for Updates
Safety and Efficacy of a Drug Eluting Slim Modiolar Electrode Array
NCT06598059
Recruiting
This clinical study will test a new type of cochlear implant known as CI632D. This experimental cochlear implant has been designed to slowly release a drug called dexamethasone. Dexamethasone works to ease inflammation and reduce tissue injury, which is common after any type of surgery. The goal is to learn if the dexamethasone in the CI632D implant lessens these reactions inside the ear following surgery and if this makes the implant work as well, or even better, in improving hearing than what... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/18/2025
Locations: Rocky Mountain Ear Center, Englewood, Colorado +8 locations
Conditions: Hearing Loss
Register for Updates
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
NCT06780449
Recruiting
This study will look at how well CagriSema helps people with obesity lose weight compared to a "dummy medicine". CagriSema is a new medicine developed by Novo Nordisk. CagriSema cannot yet be prescribed by doctors. The study has two parts: First part is called the main phase and will last for 2 years, and second part is called the extension phase and will last for 1 year. In the main phase participants will either get CagriSema or "dummy medicine". Which treatment participants get is decided by... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/18/2025
Locations: Valley Clinical Trials, Covina, California +37 locations
Conditions: Obesity
Register for Updates
Michigan Contraceptive Access, Research, and Evaluation Study Children: Phase 1
NCT04371900
Recruiting
This project builds on the Michigan Contraceptive Access Research and Evaluation Study (M-CARES) to evaluate the long-term effects of mothers' access to free contraceptives and reductions in unintended pregnancies on their children's well-being.
Gender:
ALL
Ages:
Between 0 years and 17 years
Trial Updated:
05/18/2025
Locations: Planned Parenthood - Ann Arbor-West, Ann Arbor, Michigan +8 locations
Conditions: Pregnancy
Register for Updates